FY results 2024

Positioned for strong growth

FY 2024 documents

Market leader in peptide API manufacturing and services

PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API). 

Business news

Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial

24 Apr 2025 - Sweden, 24 April 2025 – Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical […]

Read more
Media releases

PolyPeptide announces results of the annual General Meeting 2025

9 Apr 2025 - Baar, 9 April 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all […]

Read more

PolyPeptide video

PolyPeptide Group - Ahead on green peptide chemistry